Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System

Haley J. Appaneal(University of Rhode Island), Aisling R. Caffrey(University of Rhode Island), Luis Jódar(Pfizer (United States)), Laura Puzniak(Pfizer (United States)), Evan J Zasowski(Pfizer (United States)), Vrishali V. Lopes, John M. McLaughlin(Pfizer (United States))

Nature Communications

April 29, 2025

10.1038/s41467-025-59344-7

Cited by 26

Related Papers

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

|The Lancet|2021|1.7k

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

|The Lancet|2021|1.3k

The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in Bloodstream Infections: A Systematic Review and Meta-analysis

|Clinical Infectious Diseases|2016|544

Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis

|Critical Care Medicine|2017|234

A Multicenter Study of ICU Telemedicine Reengineering of Adult Critical Care

|CHEST Journal|2014|219